$Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)$

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)

Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL–PCNSL. Patients with refractory/relapsed (R/R) DLBCL–PCNSL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2019-04, Vol.30 (4), p.621-628
Hauptverfasser:	Ghesquieres, H., Chevrier, M., Laadhari, M., Chinot, O., Choquet, S., Moluçon-Chabrot, C., Beauchesne, P., Gressin, R., Morschhauser, F., Schmitt, A., Gyan, E., Hoang-Xuan, K., Nicolas-Virelizier, E., Cassoux, N., Touitou, V., Le Garff-Tavernier, M., Savignoni, A., Turbiez, I., Soumelis, V., Houillier, C., Soussain, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Central Nervous System Neoplasms - drug therapy Central Nervous System Neoplasms - mortality Drug Administration Schedule Female Follow-Up Studies France - epidemiology Humans Intention to Treat Analysis Intraocular Lymphoma - drug therapy Intraocular Lymphoma - mortality lenalidomide Lenalidomide - administration & dosage Lenalidomide - adverse effects Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - mortality Male Middle Aged Neoplasm Recurrence, Local - pathology primary CNS lymphoma primary vitreoretinal lymphoma Progression-Free Survival Proof of Concept Study Prospective Studies relapse Remission Induction - methods rituximab Rituximab - administration & dosage Rituximab - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!